MOTS-c Sequence: The 16-Amino-Acid Mitochondrial Peptide

The MOTS-c sequence is MRWQEMGYIFYPRKLR, a 16-amino-acid chain that starts with methionine and ends with arginine. MOTS-c is a mitochondrial-derived peptide, which means its genetic instructions sit inside mitochondrial DNA rather than the nuclear genome. Research on this peptide centers on metabolism, insulin sensitivity, and the way cells respond to exercise.

Most people looking up the sequence want three things: the exact letters, a residue-by-residue map, and a sense of how it compares with other research peptides. This article covers all three. MOTS-c is a laboratory research chemical, not an approved medication, and nothing here is medical advice.

The MOTS-c Sequence in One-Letter and Three-Letter Code

In standard one-letter notation, the sequence is MRWQEMGYIFYPRKLR. In three-letter notation, it reads Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg.

Two features stand out in that table. The peptide contains no cysteines, so it cannot form the internal disulfide bridges that stabilize many other small peptides. It also carries a net positive charge of roughly +2 at physiological pH, because three basic residues (two arginines and one lysine) outweigh a single acidic glutamate.

Where the MOTS-c Sequence Comes From

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c. Its sequence is encoded inside the 12S ribosomal RNA region of mitochondrial DNA, a stretch that scientists long assumed was purely structural. A 2015 paper in Cell Metabolism identified the open reading frame and showed that mitochondria can produce and release the peptide.

The 16-residue chain is reported to be identical in mice and humans. That level of conservation is unusual and is one reason animal studies on MOTS-c attract so much attention. When researchers refer to the mots-c peptide sequence, they are almost always describing this same 16-letter chain.

Because the peptide is made inside mitochondria and later acts in the cytosol and nucleus, it is often called a retrograde signal, meaning a message sent from the mitochondria back to the rest of the cell. Curiosity about the mots c sequence has grown alongside broader interest in mitochondrial-derived peptides.

Why the Sequence Matters for Function

Sequence determines shape, charge, and how a peptide interacts with cells, and MOTS-c is a clear example.

• AMPK activation. In cell and animal models, MOTS-c activates AMPK, an energy-sensing enzyme that shifts cells toward catabolism.
• Glucose handling. Studies in mice report improved glucose uptake and insulin sensitivity after MOTS-c administration.
• Folate-methionine cycle. Some work links the peptide to the methionine cycle and to how cells manage oxidative stress.
• Nuclear signaling. MOTS-c has been observed moving into the nucleus, where it appears to influence gene expression under stress.

Human data remain thin. Circulating MOTS-c levels have been associated with insulin sensitivity and with exercise in observational studies, but association is not causation. MOTS-c levels also tend to decline with age.

MOTS-c Sequence vs AOD-9604

AOD-9604 is a 16-amino-acid fragment of human growth hormone, and MOTS-c is a 16-amino-acid mitochondrial peptide. Both are the same length, yet they are unrelated in origin, sequence, and mechanism.

The quickest way to settle aod 9604 vs mots-c is to compare the letters. YLRIVQCRSVEGSCGF shares nothing with MRWQEMGYIFYPRKLR, so the two peptides cannot substitute for one another. AOD-9604 was derived from growth hormone; MOTS-c comes from mitochondrial DNA.

Do People Combine MOTS-c With Other Peptides?

Online forums and some vendors promote aod-9604 and mots-c together, typically pairing a metabolic peptide with a fat-metabolism fragment. Another common discussion involves the aod-9604 mots-c tesamorelin stack, which adds a growth-hormone-releasing hormone analog to the mix.

Two practical points matter here. Tesamorelin is the only compound in that group with FDA approval for a specific medical condition, HIV-associated lipodystrophy, and it is a prescription drug with real side effects such as injection-site reactions and elevated IGF-1. There are also no published human trials of MOTS-c combined with AOD-9604, so any stacking protocol is speculative.

• No human safety data exist for the MOTS-c and AOD-9604 combination.
• Overlapping side-effect profiles make reactions hard to trace.
• Product purity varies widely between suppliers.

Safety, Legal Status, and What the Sequence Cannot Tell You

Knowing the sequence does not tell you whether a product is safe or pure. MOTS-c is not approved by the FDA for any human use, and the same is true for AOD-9604. Both are typically sold as research chemicals, and quality depends on the supplier's synthesis and testing standards.

The only MOTS-c-related compound to reach human trials was CB4211, an analog studied in an early-phase trial for nonalcoholic steatohepatitis. That program was later discontinued, and no phase 3 data on MOTS-c exist.

Anyone considering a research peptide should speak with a licensed healthcare professional first. Self-dosing carries risks that include injection-site reactions, immune responses, and unknown long-term effects.

Bottom Line

The MOTS-c sequence is MRWQEMGYIFYPRKLR, a 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. Its net positive charge, lack of cysteines, and strong conservation across species set it apart from other research peptides.

MOTS-c is not FDA-approved for human use, and clinical evidence in people remains limited. Treat the sequence data as reference material for research, not as a treatment plan.